연구동향 분석

Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis

Ying Yang Dong Wang Lei Cui Hong-Hao Ma Li Zhang Hong-Yun Lian Qing Zhang Xiao-Xi Zhao Li-Ping Zhang Yun-Ze Zhao Na Li Tian-You Wang Zhi-Gang Li Rui Zhang 년

논문상세정보
인용/피인용

' Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis' 의 참고문헌

  • Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis
    Heritier S [2015]
  • Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
    Hyman DM [2015]
  • Treatment of Langerhans cell histiocytosis : role of BRAF/MAPK inhibition
    Abla O [2015]
  • Sustained response of three pediatric BRAF(V600E)mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
    Toll SA [2019]
  • Recurrent BRAF mutations in Langerhans cell histiocytosis
  • Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma
    Yamazaki N [2018]
  • Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E)or BRAF(V600K)mutations treated with adjuvant dabrafenib plus trametinib(COMBI-AD) : a randomised, placebo-controlled, phase 3 trial
  • Longterm disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition
    Awada G [2018]
  • Langerhans-cell histiocytosis
    Allen CE [2018]
  • Langerhans cell histiocytosis : a neoplastic disorder driven by Ras-ERK pathway mutations
    Tran G [2018]
  • LCH evaluation and treatment guidelines
  • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    Chapman PB [2011]
  • Improved overall survival in melanoma with combined dabrafenib and trametinib
    Robert C [2015]
  • HLH-2004 : diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
    Henter JI [2007]
  • Dramatic transient improvement of metastatic BRAF(V600E)-mutated Langerhans cell sarcoma under treatment with dabrafenib
    Mourah S [2015]
  • Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases(COMBI-MB) : a multicentre, multicohort, open-label, phase 2 trial
    Davies MA [2017]
  • Dabrafenib in BRAF-mutated metastatic melanoma : a multicentre, open-label, phase 3 randomised controlled trial
    Hauschild A [2012]
  • Comparative safety of BRAF and MEK inhibitors(vemurafenib, dabrafenib and trametinib)in first-line therapy for BRAFmutated metastatic melanoma
    Cebollero A [2016]
  • Common Terminology Criteria for Adverse Events (CTCAE)
  • Clinical research of pulmonary Langerhans cell histiocytosis in children
    Wang D [2018]
  • Circulating cell-free BRAF(V600E)as a biomarker in children with Langerhans cell histiocytosis
    Heritier S [2017]
  • CNS Langerhans cell histiocytosis : common hematopoietic origin for LCH-associated neurodegeneration and mass lesions
    McClain KL [2018]
  • BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy
    Heritier S [2016]
  • BRAF inhibitors in cancer therapy
  • BRAF V600E mutation : a significant biomarker for prediction of disease relapse in pediatric Langerhans cell histiocytosis
    Ozer E [2019]
  • A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors
    Kieran MW [2019]